Legal 500

  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers

  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…

  • In-House

    • In-House Content
    • GC Powerlist

  • Knowledge Centre

    • Data Products
    • Legal Business
    • News & Developments

    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Contact us
  • Deutschland DE
  • Paris FR

  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers

  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…

  • In-House

    • In-House Content
    • GC Powerlist

  • Knowledge Centre

    • Data Products
    • Legal Business
    • News & Developments

    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Data Protection policies
  • Cookies Policy
  • Supplier Code of Conduct
  • Modern Slavery and Human Trafficking Statement
  • Contact Us
  • home
  • Intelligence
  • Search

Your search for ‘Rothwell, Figg, Ernst & Manbeck, P.C.’ returned 53 results

Use advanced search filters to refine your search

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Tysabri® (Natalizumab) Litigation Begins

    On September 9, 2022, Biogen Inc. and Biogen MA Inc. ("Plaintiffs") filed suit against Sandoz Inc., Sandoz International GMBH, Sandoz GMBH, and Polpharma Biologics S.A. (collectively, "Defendants")...
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Purple Book Update – Regeneron's EYLEA (aflibercept)

    Patents related to Regeneron's EYLEA (aflibercept) were recently added to the Purple Book.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
Article

Biden Signs Executive Order Implementing Privacy-Shield Replacement For EU-US Data Transfers

Today, October 7, 2022, President Joe Biden signed an executive order implementing a new privacy framework for data being shared between Europe and the United States.
United StatesPrivacy
Rothwell, Figg, Ernst & Manbeck, P.C.
Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Humira's End Of Reign

    On March 8, 2022, Alvotech announced that it has executed a U.S. settlement agreement with Abbvie that grants Alvotech non-exclusive rights to market AVT02 (adalimumab) in the U.S starting July 1, 2023.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    First BIPA Trial Ever Results In $228M Judgment Against Company That Hired Out Fingerprint Processing Activities

    Yesterday, October 12, 2022, was the first time that a case under the Illinois Biometric Information Privacy Act (BIPA) went to trial – and the result was a big win for the Plaintiffs...
    United StatesPrivacy
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Raising A New Rationale Or Elaborating On A Previously Raised Issue?

    In Everstar Merch. Co. v. Willis Elec. Co., No. 2021-1882, 2022 WL 1089909 (Fed. Cir. Apr. 12, 2022), the Federal Circuit provided guidance to distinguish between raising a new argument...
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Key Lessons From Google's Settlement To Pay A Record $391 Million Fine For Data Collection Practices

    Google agrees to pay a historic $391.5 million to settle with attorneys general from 40 U.S. states for misleading users about its location tracking and collection practices.
    United StatesPrivacy
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    CCPA Enforcement – California AG Bonta Announces Settlement With Sephora

    California Attorney General Rob Bonta announced yesterday a settlement reached with beauty product retailer, Sephora, Inc. (Sephora), resolving allegations that Sephora violated...
    United StatesPrivacy
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Merck And Orna Therapeutics Join Forces In Circular RNA Collaboration

    On August 16, 2022, Merck (NYSE: MRK) and Orna Therapeutics each announced that they entered into a collaboration agreement relating to the discovery, development and commercialization...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    New Interim Process At The PTAB For Decision Circulation And Internal Review

    Recently, the Patent Trial and Appeal Board (PTAB) announced a new interim procedure for decision circulation and internal review. This interim procedure is aimed at promoting feedback...
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Party Stipulations During IPR: Incompatible With The Statutory Scheme?

    In late December, in Intel Corp. v. Qualcomm Inc., 2020-1828 (Fed. Cir. Dec. 28, 2021), the Federal Circuit found the PTAB erred by accepting Intel's stipulation concerning the indefiniteness of a means-plus-function claim term.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    NRG2GO Nutritional Supplement Brand Wins Trademark Opposition

    A recent trademark opposition decision shows that protecting your nutritional supplement trademark is good for overall brand health.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Roots® Apparel Brand Prevails In Trademark Opposition

    A recent trademark opposition is a lesson in how to properly establish a likelihood of confusion for apparel goods.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    PTAB Sides With Broad In Patent Dispute Over CRISPR Gene Editing Of Eukaryotic Cells

    On February 28, 2022, the Patent Trial and Appeal Board (PTAB) issued a decision in Interference No. 106,115, which granted the Broad Institute, Massachusetts Institute of Technology, and Harvard University...
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Rehearing Denied In Federal Circuit's Ruling Against Tecfidera® Patent For Lack Of Written Description

    On March 16, 2022, the Federal Circuit denied Biogen's petition for rehearing of its November 2021 decision in Biogen Int'l GmbH v. Mylan Pharms., Inc., 18 F.4th 1333, 1343 (Fed. Cir. 2021).
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Coherus Scores First Interchangeable Biosimilar Approval For Lucentis®

    On August 2, 2022, Coherus BioSciences announced that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Federal Circuit Gives Win For Patent Owners Seeking To Amend Claims At The PTAB

    In American National v. Sleep Number Corporation, the Court of Appeals for the Federal Circuit ("CAFC") affirmed the Patent Trial and Appeal Board's ("Board") decision to allow a patent owner...
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Medical Trademark Rejected For Improper Specimens Of Use

    A recent appeal of a trademark application refusal shows the importance of filing proper specimens of use.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    Senators Urge Regulators To Block And Clear Patent Thickets

    Patent thickets, particularly those involving pharmaceutical patents, appear to have caught the ire of many U.S. senators.
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.
  • Article

    How To Effectively Use Patent Counsel To Navigate The USPTO's Duty Of Candor Guidance Regarding FDA Submissions

    The United States Patent and Trademark Office (USPTO) issued updated guidance on the duty of candor and duty to disclose in relation to submissions made to other government agencies...
    United StatesIntellectual Property
    Rothwell, Figg, Ernst & Manbeck, P.C.
    Rothwell, Figg, Ernst & Manbeck, P.C.

    • Showing 1–20 of 53 results

    Next
    Legal Intelligence Newsletters